TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.;TEVA PHARMACEUTICAL INDUSTRIES LTD.
发明人:
HAYARDENY, LIAT,ACHIRON, ANAT,GUREVICH, MICHAEL
申请号：
CA2922958
公开号：
CA2922958A1
申请日:
2014.09.12
申请国别(地区):
CA
年份:
2015
代理人:
摘要：
This invention provides a method of predicting clinical responsiveness to laquinimod therapy in a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising evaluating expression of a biomarker in the subject. This invention also provides a method of treating said subject comprising determining whether the subject is a laquimmod-responder by evaluating expression of a biomarker. Also provided is laquinimod or a pharmaceutical composition comprising laquinimod for use in treating said subject, and a therapeutic package for use in dispensing to said subject, wherein the subject has been identified as a laquimmod-responder or expression of a biomarker in the subject is up-regulated or suppressed.
